Pricing Log in Create free account

Biofrontera Inc. (BFRI) vs InMed Pharmaceuticals Inc. (INM)

Biofrontera Inc. and InMed Pharmaceuticals Inc. are both Drug Manufacturers Specialty & Generic companies. Biofrontera Inc. is the larger, with a market value of $12.6M against $7.3M — 1.7× the size. InMed Pharmaceuticals Inc. grew revenue faster over the last twelve months: 19.4% against 17.8%. InMed Pharmaceuticals Inc. has the higher net margin (0.00% vs −13.8%) and the higher return on invested capital (0.00% vs −69.5%). Across the 17 metrics below, Biofrontera Inc. leads on 9 and InMed Pharmaceuticals Inc. on 8.

Valuation

Metric BFRI INM Drug Manufacturers Specialty & Generic median
P/E n/m n/m 19.25
P/S 0.23 0.95 2.11
P/B 1.78 5.11 1.78
Price to free cash flow n/m n/m 16.14
EV/EBITDA n/m n/m 12.58
EV/Sales 0.23 0.58 2.73
Earnings yield (54.88%) (228.36%) (4.38%)
Free cash flow yield (74.83%) (158.00%) 0.00%

Profitability

Metric BFRI INM Drug Manufacturers Specialty & Generic median
Gross margin 79.25% 26.27% 53.94%
Operating margin (14.22%) 0.00% 0.00%
Net margin (13.78%) 0.00% 0.00%
Free cash flow margin (17.17%) 0.00% 0.00%
Return on equity (988.35%) (179.09%) (0.40%)
Return on assets (28.80%) (139.63%) (3.32%)
Return on invested capital (69.45%) 0.00% 0.00%

Growth

Metric BFRI INM Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) 17.83% 19.38% 10.01%
EPS growth (last fiscal year) 67.70% 62.68% 49.06%
Revenue growth, 5-year CAGR 17.21% — 6.74%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric BFRI INM Drug Manufacturers Specialty & Generic median
Debt to equity 0.78 0.00 0.05
Current ratio 1.18 1.37 2.31
Net debt to EBITDA 0.17 0.20 0.97

Dividend

Metric BFRI INM Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.57%
Payout ratio — — 0.27

Size

Metric BFRI INM Drug Manufacturers Specialty & Generic median
Market cap 12.58m 7.31m 276.90m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack